# Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases

> **NCT00327652** · PHASE1 · COMPLETED · sponsor: **Anza Therapeutics, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Neoplasm Metastasis
- Liver Neoplasms
- Carcinoma

## Interventions

- **DRUG:** CRS-100

## Key facts

- **NCT ID:** NCT00327652
- **Lead sponsor:** Anza Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-02
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2008-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00327652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00327652, "Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00327652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*